PERSPECTIVE THERAPEUTICS INC (CATX) Stock Price & Overview
NYSEARCA:CATX • US46489V3024
The current stock price of CATX is 5.265 USD. Today CATX is down by -1.59%. In the past month the price increased by 10.54%. In the past year, price increased by 106.56%.
CATX Key Statistics
- Market Cap
- 599.736M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.14
- Dividend Yield
- N/A
CATX Stock Performance
CATX Stock Chart
CATX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CATX. When comparing the yearly performance of all stocks, CATX is one of the better performing stocks in the market, outperforming 96.88% of all stocks.
CATX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CATX. The financial health of CATX is average, but there are quite some concerns on its profitability.
CATX Earnings
On January 30, 2026 CATX reported an EPS of -0.35 and a revenue of 209.00K. The company missed EPS expectations (-5.16% surprise) and missed revenue expectations (-8.46% surprise).
CATX Forecast & Estimates
20 analysts have analysed CATX and the average price target is 12.95 USD. This implies a price increase of 145.89% is expected in the next year compared to the current price of 5.265.
For the next year, analysts expect an EPS growth of -51.2% and a revenue growth -21.09% for CATX
CATX Groups
Sector & Classification
CATX Financial Highlights
Over the last trailing twelve months CATX reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 22.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.89% | ||
| ROE | -43.68% | ||
| Debt/Equity | 0.01 |
CATX Ownership
CATX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.31 | 401.392B | ||
| AMGN | AMGEN INC | 16.6 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.89 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.92 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.94 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.16 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.03 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CATX
Company Profile
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 138 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Company Info
IPO: 2002-05-31
PERSPECTIVE THERAPEUTICS INC
2401 Elliott Avenue, Suite 320
Seattle WASHINGTON US
Employees: 138
Phone: 18009279800
PERSPECTIVE THERAPEUTICS INC / CATX FAQ
Can you describe the business of PERSPECTIVE THERAPEUTICS INC?
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 138 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Can you provide the latest stock price for PERSPECTIVE THERAPEUTICS INC?
The current stock price of CATX is 5.265 USD. The price decreased by -1.59% in the last trading session.
Does PERSPECTIVE THERAPEUTICS INC pay dividends?
CATX does not pay a dividend.
What is the ChartMill rating of PERSPECTIVE THERAPEUTICS INC stock?
CATX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CATX stock to perform?
20 analysts have analysed CATX and the average price target is 12.95 USD. This implies a price increase of 145.89% is expected in the next year compared to the current price of 5.265.
What is the ownership structure of PERSPECTIVE THERAPEUTICS INC (CATX)?
You can find the ownership structure of PERSPECTIVE THERAPEUTICS INC (CATX) on the Ownership tab.
What is the Short Interest ratio of PERSPECTIVE THERAPEUTICS INC (CATX) stock?
The outstanding short interest for PERSPECTIVE THERAPEUTICS INC (CATX) is 9.49% of its float.